Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

6

Revenue 2017

Remicade

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Remicade was produced by Johnson & Johnson, Mitsubishi Tanabe Pharma and Merck & Co..

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

Remicade (infliximab) facing increasing competition from biosimilars. ... TNF inhibitor Remicade’s sales fell by around 15% in the first nine months of the year to $4.1bn, mainly due to price reductions, while Tremfya sales were $369m globally

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP Sandoz’ Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera.

The good, the bad and the ugly

The good, the bad and the ugly Another top-selling drug also experienced decline for similar reasons: J&J’s Remicade - still in the top 10 best-selling products of 2017 - fell back by 7.5% due to

J&J files would-be prostate cancer blockbuster in US

J&J files would-be prostate cancer blockbuster in US up and the threat of biosimilar competition to big-selling biologic drugs such as Remicade (infliximab) is becoming ‘more measured’.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics